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At present no reports on gene expression profiling of liver metastases from colorectal cancer are available. We identified two
different signatures using Affymetrix platform: epidermal growth factor receptor pathway was upregulated in metachronous lesions,
whereas the pathway mainly related to angiogenesis was in synchronous lesions. Synchronous or metachronous liver metastases
could be treated differently on the basis of different molecular pathways.
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The liver is the most common site of metastases from colorectal
cancer. About 25% of patients presented liver metastases at
diagnosis and about 70% of patients develop a liver recurrence
after radical surgery of colorectal tumours (50% of patients with
stage III and 20% with stage II cancer) (Penna and Nordlinger,
2002). The treatment of metastases from colorectal cancer is
complicated and still controversial (Biasco et al, 2006; Ercolani
et al, 2006). For unresectable lesions, the medical systemic
treatment is considered the standard option. During the last few
years, novel biological agents such as monoclonal antibodies
inhibiting growth factor receptors or angiogenesis have been
combined with chemotherapy to improve the outcome of patients
affected by colorectal cancer (Cunningham et al, 2004; Hurwitz
et al, 2004; Saltz et al, 2004, 2007; Giantonio et al, 2007; Tabernero
et al, 2007; Van Cutsem et al, 2007). In clinical practice the choice
of treatments are based only on published clinical data with the
respect to first-, second- and third-line therapy. However, the
natural history, the clinical scenario and the prognosis of liver
metastases may be different. From a general clinical point of view,
liver metastases are classified as ‘synchronous’ lesions if they are
present at diagnosis of disease or if they occur less than 6 months
after surgery of primary tumour and ‘metachronous’ lesions if they
occur after more than 6 months. At present, the systemic therapy is
not differentiated for these two clinical settings. The aim of this
study is to study the gene expression profiling of synchronous and
metachronous liver metastases using Affymetrix platform to
identify molecular patterns as a possible basis for the choice of
systemic therapies and for response prediction.
MATERIALS AND METHODS
Patients and tissues
This study was approved by the local Ethical Committee (approval
number: 6/2005/U/Tess). Fresh tissue specimens from liver
metastases of 18 patients who had undergone liver surgery were
collected after written consent. The specimens were obtained from
a single lesion for each patient to avoid the inter-lesion biological
variability and immediately frozen in the operating room in liquid
nitrogen. The lesions were classified as 10 synchronous and 8
metachronous lesions. The patient’s characteristics are described
in Table 1.
Microarray analysis
Total RNA was extracted from frozen tumour specimens using
TRIzol Reagent (Invitrogen Life Technologies, Carlsbad, CA, USA),
labelled and hybridised to HG-U133Plus 2.0 Affymetrix arrays
following the manufacturer’s instructions. Data shown in this
publication have been deposited in the NCBI Gene Expression
Omnibus database. Raw data were background-subtracted,
normalised and summarised with the robust multi-array average
(RMA) algorithm implemented in the affy package of Bioconduc-
tor (http://www.bioconductor.org). Routine quality controls
available in the affy and affyPLM packages of Bioconductor were
performed to check for the presence of artifacts and for the
consistency of normalisation across arrays. Probes poorly
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sexpressed in more than 8 samples out of 18 or not changing
among the samples, based on interquartile range (IQR) calculation,
were excluded from further analysis. Genes differentially
expressed between synchronous and metachronous lesions
were selected by the permutation-based t-statistics implemented
in the SAM algorithm (Tusher et al, 2001). SAM computes the
false discovery rate (FDR, the proportion of false positives in
output list of differential genes) by permutations of the sample
labels. We set the FDR threshold for significance at 5%. All the
analyses were performed with R 2.6.0 and Bioconductor packages.
Heatmap representation of differentially expressed genes was
performed with MeV software (http://www.tm4.org/mev.html),
and pathway analysis with EASE tool (http://david.abcc.ncifcrf.
gov/), calculating the significance of enrichment of a pathway by
the EASE score.
Following the suggestions from the microarrays analysis and
in order to confirm the data, quantitative determinations were
performed of most clinical relevant proteins such as cyclo-
oxygenase-2 (COX-2) and epidermal growth factor receptor
(EGFr).
Real-time PCR quantification of COX-2 and EGFr
Total RNA was reverse transcribed using Superscript II
(Invitrogen Life Technologies) with oligo-dT primers, according
to the manufacturer’s guidelines. Gene-specific primers and
TaqMan probes were designed with the Beacon Designer
2.0 Software (Premier Biosoft International, Palo Alto, CA, USA)
and real-time PCR was performed using an iCycler apparatus
(Bio-Rad Laboratories, Hercules, CA, USA). The cycle
numbers were recorded when the accumulated PCR products
crossed an arbitrary threshold (CT or threshold cycle) and CT
values were used to calculate the expression levels of COX-2 and
EGFr relative to the average of two housekeeping genes b-actin and
18S rRNA.
Protein extraction and COX-2 western blot analysis
Frozen tissues were homogenised using lysis buffer (50mM Tris pH
7.4, 150mM NaCl, 2mM MgCl2, 1% Triton X-100, 10% glycerol,
2m M EGTA, 1mM DTT) containing protease inhibitors
(10mgml
 1 aprotinin and leupeptin, 5mgml
 1 pepstatin, 1mM
PMSF) and phosphatase inhibitors (50mM NaF, 10mM Na4P2O7,
1m M Na3VO4,3m M H2O2). Samples were processed according to
the standard procedures: anti COX-2 antibody (BD Transduction
Laboratories, Lexington, KY, USA), incubations conditions: 1:500
in TBS-TB buffer (50mM Tris-HCl, pH 7.4, 150mM NaCl, 1%
Tween 20 and 3% bovine serum albumin) at 41C o.n.
ELISA quantification of EGFr
The concentration of total EGFr was assessed using the ELISA kits
purchased from Biosource International Inc. (Camarillo, CA,
USA). Protein lysates from A431 and SW620 cell lines were used
respectively as positive and negative controls, to verify the
specificity of the EGFr ELISA assays. Protein quantification was
expressed using box plots. Significance was analysed by non-
parametric log-rank test (Mann–Whitney test). A P-value less than
0.05 was considered significant. The statistical calculations were
performed using StatView 5.0 statistical software (SAS Institute
Inc., Cary NC, USA). (Details on Materials and Methods are
available in Supplementary Information).
RESULTS
The gene expression analysis identified 49 genes upregulated in
metachronous and 55 genes upregulated in synchronous
metastases with a FDR o5% (Figure 1). Among these, functional
analysis of differential genes showed two main deregulated
pathways of clinical interest in medical oncology: EGFr signalling
pathway (P¼0.065, modified Fisher’s exact test) and eicosanoid
metabolism (P¼0.012). Key genes belonging to these path-
ways are EGFr, PIK3R1, the regulatory subunit 1 (p85-a)o f
the phosphoinositide-3-kinase, COX-2, COX1 and ALOX5AP,
the activating protein of the arachidonate 5-lipoxygenase. In
particular, EGFr was overexpressed in metachronous lesions
(P¼0.046, Mann–Whitney test) and COX-2 gene was over-
expressed in synchronous lesions (P¼0.012) (Figure 2A). To
confirm the differential expression of these two genes, a
quantitative analysis of EGFR and COX-2 mRNA with real-time
PCR, and of protein levels by western blot (COX-2) and ELISA
test (EGFr) were performed. Both analyses showed that COX-2 was
overexpressed in synchronous lesions (P¼0.033 and P¼0.034)
and EGFr was overexpressed in metachronous lesions (P¼0.013
and P¼0.043), respectively, at the mRNA and protein levels
(Figure 2B and C).
DISCUSSION
Over the few last years, the gene expression profiling analysis with
microarray technology has shown a great potential for clinical
application in medical oncology (Bittner et al, 2000; Perou et al,
2000; Dhanasekaran et al, 2001; Garber et al, 2001; Takahashi et al,
2001; van ‘t Veer et al, 2002; Van de Vijver et al, 2002; Ayers et al,
2004; Jones et al, 2005; Dressman et al, 2006; Bonnefoi et al, 2007;
Bueno-de-Mesquita et al, 2007; Kim et al, 2007). Several data have
already been published on the powerful prognostic role of the gene
signature in many tumours (Bittner et al, 2000; Dhanasekaran
et al, 2001; Garber et al, 2001; Takahashi et al, 2001; van ‘t Veer
et al, 2002; Van de Vijver et al, 2002; Jones et al, 2005; Bueno-
de-Mesquita et al, 2007) and also on the predictor role of complete
response to neoadjuvant chemotherapy especially in breast cancer
(Ayers et al, 2004; Dressman et al, 2006; Bonnefoi et al, 2007; Kim
et al, 2007). Concerning colorectal cancer, several reports are
available but they are mostly aimed at improving the diagnosis on
a molecular basis differentiating between cancer, adenoma and
Table 1 Patient’s and tumours characteristics
Number of patients Total 18
Sex
Male 10 (66.6%)
Female 8 (33.3%)
Age
Median 63 years
Range 41–77 years
Primary tumour site
Right colon 6 (33.3%)
Left colon 8 (44.4%)
Rectum 4 (22.2%)
Synchronous/metachronous
Synchronous 10 (55.5%)
Metachronous 8 (44.4%)
Single/multiple metastases
Single 4 (22.2%)
Multiple 14 (77.7%)
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Figure 1 Heatmap representation of genes differentially expressed between metachronous (M) and synchronous (S) liver metastases: in blue
(underexpressed genes, log2 ratio¼ 3) and in red (overexpressed genes, log2 ratio¼3) representing the two extremeties of gene expression. Log ratios
are referred to average expression level in all samples for each gene.
Gene expression profiling of liver metastases
MA Pantaleo et al
1731
British Journal of Cancer (2008) 99(10), 1729–1734 & 2008 Cancer Research UK
G
e
n
e
t
i
c
s
a
n
d
G
e
n
o
m
i
c
snormal mucosa, and also to evaluating the potential for metastases
developing (Alon et al, 1999; Notterman et al, 2001; Yanagawa
et al, 2001; Bertucci et al, 2004; Koehler et al, 2004; Li et al, 2004;
Wang et al, 2004; Eschrich et al, 2005). Moreover, the studies have
been mainly conducted on primary tumours and only very few
data are available on metastases (Yanagawa et al, 2001; Koehler
et al, 2004).
This study first reports the gene expression profiling of liver
metastases from colorectal cancer. Our results showed that the
molecular background of liver metastases may be different and
that EGFR and COX-2 are overexpressed in metachronous and
synchronous metastases, respectively. These findings improve the
current knowledge on biological background of colorectal liver
metastases. Furthermore, they may also have some clinical
implications, because they suggest that medical treatments of
patients with liver metastases may be differentiated in these two
clinical setting according to their different biological background.
Therapies based on EGFr pathway inhibition may be considered
for metachronous metastases (such as monoclonal antibodies
cetuximab or panitumumab) and therapies based on angiogenesis
cross-talking pathways inhibition (such as the monoclonal anti-
body bevacizumab, COX-2 inhibitors or small molecules tyrosin
kinase inhibitors with antiangiogenetic properties) for the
synchronous metastases.
Regarding EGFr pathway in colorectal cancer, at present,
no molecular factors are predictive of response to cetuximab or
panitumumab-based treatments except for K-ras mutations
(De Roock et al, 2008; Lie `vre et al, 2008). In fact, it is already
well known that morphological expressions of the receptor studied
with immunohistochemistry is inadequate and other evaluations
did not reach any conclusive data (Dei Tos and Ellis, 2005; Moroni
et al, 2005; Vallbo ¨hmer et al, 2005; Lenz et al, 2006). In our study,
the expression of EGFr has been evaluated using three different
molecular techniques that provide quantitative information that,
in our opinion, may be a more accurate and reliable study of EGFr
status in colorectal cancer as a predictor of response to EGFr
inhibitors.
The COX-2 upregulation in synchronous metastases supports
its association with tumour invasiveness and metastatic
process because COX-2 affects cell proliferation, tumour growth,
angiogenesis, apoptosis resistance and immune response
(Sheng et al, 1997; Chen et al, 2001). COX-2 overexpression may
suggest a more aggressive phenotype of this kind of metastases
that require a treatment preferentially directed against tumour
angiogenesis, such as bevacizumab-based combinations or a
treatment creating an unfavourable environment for tumour
growth as recently published with COX-2 inhibitors (de Heer
et al, 2008).
As future perspective, from a biological point of view, it could be
interesting to compare gene expression profiling of metastases
and primary tumour to better understand the molecular
mechanisms involved in the metastatic process and to early
mRNA quantitative analysis (RT–PCR)
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Figure 2 COX-2 and EGFr differences in synchronous and metachronous metastases. (A) mRNA expression analysed by microarray and shown as
normalised expression value as calculated by RMA algorithm; (B) mRNA expression with real-time PCR analysis; (C) protein quantification with western
blotting for COX-2 and ELISA for EGFr.
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development.
In conclusion, synchronous and metachronous liver metastases
from colorectal cancer have a different gene expression signature and
a different expression of EGFR and COX-2 that may be the basis for
choosing the medical treatment. These preliminary results need to be
confirmed in larger series and, in the future, their role as molecular
predictors should be also investigated in clinical trials.
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